Lexicon Pharmaceuticals | LXRX - Le Chiffre D'Affaires De Vente





Ventes Changement Date
Abbott USD 11.46B 90M 2025-12
Acadia Pharmaceuticals USD 284M 5.4M 2025-12
Agios Pharmaceuticals USD 19.97M 7.07M 2025-12
Akebia Therapeutics USD 57.62M 1.14M 2025-12
Alnylam Pharmaceuticals USD 1.1B 150M 2025-12
AstraZeneca USD 15.5B 313M 2025-12
BioMarin Pharmaceutical USD 875M 99M 2025-12
Coherus Biosciences USD 12.75M 1.18M 2025-12
Eli Lilly USD 19.3B 1.7B 2025-12
Esperion Therapeutics USD 168.45M 81.14M 2025-12
Halozyme Therapeutics USD 451.76M 97.76M 2025-12
Illumina USD 1.16B 80M 2025-12
Insmed USD 263.8M 121.8M 2025-12
Ironwood Pharmaceuticals USD 47.71M 74.35M 2025-12
J&J USD 24.6B 610M 2025-12
Lexicon Pharmaceuticals USD 5.49M 8.69M 2025-12
MacroGenics USD 41.23M 31.61M 2025-12
MannKind USD 111.96M 29.83M 2025-12
Merck USD 16.4B 880M 2025-12
Moderna USD 678M 342M 2025-12
Novartis USD 13.86B 50M 2025-12
PTC Therapeutics USD 164.7M 46.3M 2025-12
Puma Biotechnology USD 80.54M 33.46M 2024-09
Sarepta Therapeutics USD 442.9M 43.5M 2025-12
Thermo Fisher Scientific USD 12.21B 1.09B 2025-12
Ultragenyx Pharmaceutical USD 207M 47M 2025-12
United Therapeutics USD 790.2M 9.3M 2025-12
Vanda Pharmaceuticals USD 198.77M 151.12M 2024-12